JP2023179556A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023179556A5 JP2023179556A5 JP2023160419A JP2023160419A JP2023179556A5 JP 2023179556 A5 JP2023179556 A5 JP 2023179556A5 JP 2023160419 A JP2023160419 A JP 2023160419A JP 2023160419 A JP2023160419 A JP 2023160419A JP 2023179556 A5 JP2023179556 A5 JP 2023179556A5
- Authority
- JP
- Japan
- Prior art keywords
- antibodies
- cancer
- derivatives
- use according
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 12
- 239000002184 metal Substances 0.000 claims 11
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 230000004069 differentiation Effects 0.000 claims 7
- 150000003904 phospholipids Chemical group 0.000 claims 7
- 230000002285 radioactive effect Effects 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 5
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 5
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 239000013522 chelant Substances 0.000 claims 5
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 5
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 229940126546 immune checkpoint molecule Drugs 0.000 claims 4
- 102100038078 CD276 antigen Human genes 0.000 claims 3
- 102100031351 Galectin-9 Human genes 0.000 claims 3
- 101710121810 Galectin-9 Proteins 0.000 claims 3
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 claims 3
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims 3
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 3
- 239000002738 chelating agent Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229960001438 immunostimulant agent Drugs 0.000 claims 3
- 239000003022 immunostimulating agent Substances 0.000 claims 3
- 230000003308 immunostimulating effect Effects 0.000 claims 3
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims 3
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 150000003384 small molecules Chemical class 0.000 claims 3
- HHLZCENAOIROSL-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical group OC(=O)CN1CCNCCN(CC(O)=O)CCN(CC(O)=O)CC1 HHLZCENAOIROSL-UHFFFAOYSA-N 0.000 claims 2
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 claims 2
- SYFGLWDDLZQFNI-UHFFFAOYSA-N 2-[4-(carboxymethyl)-1,4,8,11-tetrazabicyclo[6.6.2]hexadecan-11-yl]acetic acid Chemical compound C1CN(CC(O)=O)CCCN2CCN(CC(=O)O)CCCN1CC2 SYFGLWDDLZQFNI-UHFFFAOYSA-N 0.000 claims 2
- 102000007471 Adenosine A2A receptor Human genes 0.000 claims 2
- 108010085277 Adenosine A2A receptor Proteins 0.000 claims 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 2
- 101710144268 B- and T-lymphocyte attenuator Proteins 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 2
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 2
- 102100034980 ICOS ligand Human genes 0.000 claims 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 2
- 102000002698 KIR Receptors Human genes 0.000 claims 2
- 108010043610 KIR Receptors Proteins 0.000 claims 2
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 claims 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 2
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims 2
- 102000004473 OX40 Ligand Human genes 0.000 claims 2
- 108010042215 OX40 Ligand Proteins 0.000 claims 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 2
- JVHROZDXPAUZFK-UHFFFAOYSA-N TETA Chemical compound OC(=O)CN1CCCN(CC(O)=O)CCN(CC(O)=O)CCCN(CC(O)=O)CC1 JVHROZDXPAUZFK-UHFFFAOYSA-N 0.000 claims 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 229960000958 deferoxamine Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003862 glucocorticoid Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 230000006058 immune tolerance Effects 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 208000037819 metastatic cancer Diseases 0.000 claims 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 229960003330 pentetic acid Drugs 0.000 claims 2
- RMMFBFFGGLOIKT-UHFFFAOYSA-N 1,2,5,8-tetrazecane Chemical compound C1CNCCNNCCN1 RMMFBFFGGLOIKT-UHFFFAOYSA-N 0.000 claims 1
- ITWBWJFEJCHKSN-UHFFFAOYSA-N 1,4,7-triazonane Chemical compound C1CNCCNCCN1 ITWBWJFEJCHKSN-UHFFFAOYSA-N 0.000 claims 1
- WBRUPBYQJCBBBL-UHFFFAOYSA-N 2-[4-(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCNCCN(CC(O)=O)CC1 WBRUPBYQJCBBBL-UHFFFAOYSA-N 0.000 claims 1
- SOQZMTFJFHDHTP-UHFFFAOYSA-N 6-(ethylaminomethyl)pyridine-2-carboxylic acid Chemical compound CCNCC1=CC=CC(C(O)=O)=N1 SOQZMTFJFHDHTP-UHFFFAOYSA-N 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 101100294331 Drosophila melanogaster nod gene Proteins 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 108091007744 Programmed cell death receptors Proteins 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000016624 Retinal neoplasm Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 238000003782 apoptosis assay Methods 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 150000005690 diesters Chemical class 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 1
- 230000005522 programmed cell death Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 201000008933 retinal cancer Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/809,427 | 2017-11-10 | ||
| US15/809,427 US11633506B2 (en) | 2016-07-18 | 2017-11-10 | Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies |
| JP2020525860A JP2021502368A (ja) | 2017-11-10 | 2018-11-09 | 免疫療法に対する抗腫瘍免疫応答を促進するための標的化放射線療法（ｔｒｔ）の使用 |
| PCT/US2018/059927 WO2019094657A1 (en) | 2017-11-10 | 2018-11-09 | Using targeted radiotherapy (trt) to drive anti-tumor immune response to immunotherapies |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020525860A Division JP2021502368A (ja) | 2017-11-10 | 2018-11-09 | 免疫療法に対する抗腫瘍免疫応答を促進するための標的化放射線療法（ｔｒｔ）の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023179556A JP2023179556A (ja) | 2023-12-19 |
| JP2023179556A5 true JP2023179556A5 (enrdf_load_stackoverflow) | 2024-02-15 |
Family
ID=64665595
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020525860A Pending JP2021502368A (ja) | 2017-11-10 | 2018-11-09 | 免疫療法に対する抗腫瘍免疫応答を促進するための標的化放射線療法（ｔｒｔ）の使用 |
| JP2023160419A Pending JP2023179556A (ja) | 2017-11-10 | 2023-09-25 | 免疫療法に対する抗腫瘍免疫応答を促進するための標的化放射線療法（ｔｒｔ）の使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020525860A Pending JP2021502368A (ja) | 2017-11-10 | 2018-11-09 | 免疫療法に対する抗腫瘍免疫応答を促進するための標的化放射線療法（ｔｒｔ）の使用 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3706808A1 (enrdf_load_stackoverflow) |
| JP (2) | JP2021502368A (enrdf_load_stackoverflow) |
| KR (1) | KR102758660B1 (enrdf_load_stackoverflow) |
| CN (2) | CN120550150A (enrdf_load_stackoverflow) |
| CA (1) | CA3082056A1 (enrdf_load_stackoverflow) |
| IL (1) | IL274518A (enrdf_load_stackoverflow) |
| WO (1) | WO2019094657A1 (enrdf_load_stackoverflow) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022515187A (ja) * | 2018-12-21 | 2022-02-17 | アクティニウム ファーマシューティカルズ インコーポレイテッド | 癌の治療における放射免疫療法と免疫チェックポイント療法との組み合わせ |
| AU2020392166A1 (en) * | 2019-11-27 | 2022-05-26 | Gi Innovation, Inc. | Pharmaceutical composition for treatment of cancer, comprising immune checkpoint inhibitor and fusion protein including IL-2 protein and CD80 protein |
| EP3842097A1 (en) * | 2019-12-23 | 2021-06-30 | Koninklijke Philips N.V. | Planning radiation therapy using a personalized hematologic risk score |
| AU2021212659A1 (en) | 2020-01-28 | 2022-08-04 | Reflexion Medical, Inc. | Joint optimization of radionuclide and external beam radiotherapy |
| GB2610074B (en) * | 2020-03-26 | 2024-07-10 | Marigdalia Kaleth Ramirez Fort | Ultraviolet radiation treatments |
| CN111840585B (zh) * | 2020-07-20 | 2022-05-03 | 厦门大学 | 一种用于肿瘤免疫治疗的药物组合 |
| US20220395702A1 (en) * | 2021-06-10 | 2022-12-15 | Alpha Tau Medical Ltd. | Diffusing alpha-emitter radiation therapy for glioblastoma |
| IL314533A (en) * | 2022-01-28 | 2024-09-01 | Fusion Pharmaceuticals Inc | Ntsr1-targeted radiopharmaceuticals and checkpoint inhibitor combination therapy |
| WO2024258913A1 (en) * | 2023-06-16 | 2024-12-19 | Wisconsin Alumni Research Foundation | Treatment of solid tumors with a regimen of targeted radionuclide therapy and genetically engineered immune cell therapies |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7226577B2 (en) * | 2003-01-13 | 2007-06-05 | Bracco Imaging, S. P. A. | Gastrin releasing peptide compounds |
| US8540968B2 (en) | 2004-03-02 | 2013-09-24 | Cellectar, Inc. | Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof |
| WO2007013894A2 (en) * | 2004-12-20 | 2007-02-01 | Cellectar, Llc | Phospholipid ether analogs for detecting and treating cancer |
| BRPI0508425A (pt) * | 2004-03-02 | 2007-07-24 | Cellectar Llc | análogos de fosfolipìdeo como agentes diapêuticas e seus métodos |
| RU2012100765A (ru) * | 2009-06-12 | 2013-07-20 | Селлектар, Инк. | Эфирные и алкильные фосфолипидные производные для лечения рака и визуализации и детектирования раковых стволовых клеток |
| CA2989266A1 (en) * | 2015-06-25 | 2016-12-29 | Advanced Accelerator Applications | Method of treatment of neuroendocrine tumors that over-express somatostatatin receptors |
| EP3334465A1 (en) * | 2015-08-12 | 2018-06-20 | Bayer Pharma Aktiengesellschaft | Pharmaceutical combination for the treatment of cancer |
| EP3370779A1 (en) * | 2015-11-06 | 2018-09-12 | Wisconsin Alumni Research Foundation | Long-lived gadolinium based tumor targeted imaging and therapy agents |
| AU2017300361B2 (en) * | 2016-07-18 | 2024-08-01 | Wisconsin Alumni Research Foundation | Radiohalogenated agents for In Situ Immune Modulated Cancer Vaccination |
| US11633506B2 (en) * | 2016-07-18 | 2023-04-25 | Wisconsin Alumni Research Foundation | Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies |
| JP7127014B2 (ja) | 2016-07-25 | 2022-08-29 | ウイスコンシン アラムナイ リサーチ ファウンデーシヨン | 癌のイメージングおよび治療のための放射性リン脂質金属キレート |
| JP7438756B2 (ja) * | 2016-07-25 | 2024-02-27 | ウイスコンシン アラムナイ リサーチ ファウンデーシヨン | Ｉｎ ｓｉｔｕ免疫調節癌ワクチン接種のための標的化された放射線治療用キレート |
-
2018
- 2018-11-09 KR KR1020207016410A patent/KR102758660B1/ko active Active
- 2018-11-09 CN CN202510688757.2A patent/CN120550150A/zh active Pending
- 2018-11-09 CN CN201880086000.4A patent/CN111565762A/zh active Pending
- 2018-11-09 EP EP18819480.7A patent/EP3706808A1/en active Pending
- 2018-11-09 CA CA3082056A patent/CA3082056A1/en active Pending
- 2018-11-09 JP JP2020525860A patent/JP2021502368A/ja active Pending
- 2018-11-09 WO PCT/US2018/059927 patent/WO2019094657A1/en unknown
-
2020
- 2020-05-07 IL IL274518A patent/IL274518A/en unknown
-
2023
- 2023-09-25 JP JP2023160419A patent/JP2023179556A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023179556A5 (enrdf_load_stackoverflow) | ||
| US20220098302A1 (en) | Combination of dr5 agonist and anti-pd-1 antagonist and methods of use | |
| US20230398239A1 (en) | Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies | |
| JP6858558B2 (ja) | 新生物疾患の処置、減少、阻害、又は制御において使用するための、免疫調節薬 | |
| KR102758660B1 (ko) | 면역요법에 대한 항-종양 면역 반응을 유도하기 위해 표적화된 방사선요법(trt)을 이용하는 방법 | |
| BRPI0607486B1 (pt) | Anticorpo humanizado l243 contra hla-dr presente nas células hladr+,composição farmacêutica, kit e uso dos referidos anticorpos. | |
| CN109789207B (zh) | 用于原位免疫调节的癌症疫苗接种的靶向放射治疗螯合物 | |
| US20220143228A1 (en) | Her3 radioimmunotherapy for the treatment of solid cancers | |
| JP2023510309A (ja) | 持続的免疫療法 | |
| JP7492752B2 (ja) | 免疫療法のためのアジュバントとしてのグアナベンズ | |
| US20230092668A1 (en) | Radioconjugates targeting cd33 in the treatment of cancers | |
| US20230028062A1 (en) | Methods for enhancing immunity and tumor treatment | |
| JP7154634B2 (ja) | 腫瘍免疫賦活剤 | |
| EP4380632A1 (en) | Radioconjugates targeting cd33 in the treatment of cancers | |
| JP2023550462A (ja) | 固形がんの治療のためのｈｅｒ３放射免疫治療薬 | |
| US20230248855A1 (en) | Her3 radioimmunotherapy for the treatment of solid cancers | |
| AU2018366219B2 (en) | Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies | |
| JP2023538568A (ja) | がん治療における使用のためのｌｆａ－１シグナル伝達メディエーター | |
| HK40081237A (en) | Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy | |
| JP2024544518A (ja) | 癌治療のためのｔｌｒ７アゴニストおよび組合せ | |
| JP2023539246A (ja) | 腫瘍微小環境の遺伝的調節のための方法及び組成物 | |
| CN120302979A (zh) | 针对CD40和CD137的多特异性抗体与抗PD1 Ab和化学治疗的组合治疗 | |
| JPWO2021113734A5 (enrdf_load_stackoverflow) | ||
| HK1260468A1 (en) | Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy | |
| CN110352199A (zh) | 免疫检查点治疗 |